Uroplasty Inc. (NSDQ:UPI) is hoping to corner a big piece of the $20 million market for bulking agents used to treat stress unrinary incontinence now that C.R. Bard (NYSE:BCR) is no longer a player in the space.
Men's Health
Boston Scientific warns on stolen endoscopy instruments
Boston Scientific (NYSE:BSX) is warning customers about a possible risk of infection from a stolen shipment of unsterilized endoscopy, urology and women’s health instruments.
"These devices were stolen while en route to our sterilization facility sometime between April 8, 2011 and April 11, 2011," according to a May 3 notice posted on the FDA’s website.
Medtronic eyes regenerative medicine market with Tengion investment
Another Medicare domino falls for Uroplasty
Uroplasty Inc. (NSDQ:UPI) said it added most of New England to its roster of Medicare carriers after NHIC Corp. agreed to cover its UrgentPC treatment for urinary incontinence, the latest in a series of reimbursement dominoes to topple its way.
The decision, effective May 22 , puts 1.8 million Medicare patients in Maine, Massachusetts, New Hampshire, Rhode Island and Vermont under Uroplasty’s coverage umbrella, for a total of about 31 million in 35 states.
UnitedHealthcare nod sends Uroplasty shares up 15%
Shares of Uroplasty Inc. (NSDQ:UPI) surged 15 percent yesterday after the company reported a slew of positive reimbursement news, including a pickup by UnitedHealthcare, the largest health insurer in the U.S.
Health care law: A year in, doubts persist
MASSDEVICE ON CALL — One year into health care reform, sharp divides remain among Americans about the law along partisan lines, with half of the public unsure about its effects.
Fifty-two percent of Americans say they’re unsure about how the law will affect them, according to a survey of "a nationally representative random sample of 1,202 adults ages 18 and older" conducted by the Kaiser Family Foundation.
Catheter maker PercuVision wins $1.4 million loan from Ohio
Urological catheterization company PercuVision LLC was awarded a $1.4 million commercialization loan by the Ohio Dept. of Development (ODOD).
The loan will go toward a $1.9 million project in which the Westerville, Ohio-based company will create “customer demonstration units” for hospitals, COO Earl Singh said.
“That’s important to the company because our technology is new and we’re still in premarket acceptance mode,” said Singh, whose urologist brother Errol is the company’s CEO.
Urologix remains in the red for Q2
Urologix Inc. (NSDQ:ULGX) reported “disappointing” second-quarter results on Tuesday, posting a net loss of $712,000.
The Plymouth, Mass.-based company develops devices for treating enlarged prostate, or benign prostatic hyperplasia. Its Targis System uses microwave energy to heat and destroy enlarged prostate tissue as an alternative to pharmaceutical treatment.
GT Urological wraps up $4.6 million for urinary incontinence device
GT Urological LLC raised $4.56 million from the sale of equity, according to documents filed with the Securities & Exchange Commission.
Overall, the company, based in Minneapolis, is seeking $5 million to develop a device that treats patients suffering from urinary incontinence. Founder and president Dr. Gerald Timm did not immediately return a call seeking comment.
The disposable device, called ActiCuf Compression Pouch, helps men manage urine flow by applying pressure on the urethra. ActiCuf, which is worn on the penis, also captures any leaked urine.
Uroplasty loses coverage for neuromodulation device in four states
Uroplasty Inc. (NSDQ:UPI) suffered a setback for insurance coverage of its Urgent PC Neuromodulation system.
After Jan. 3, use of the posterior tibial nerve stimulation device will no longer be paid for by National Government Services, a regional Medicare carrier that operates in Connecticut, Indiana, Kentucky and New York, the company revealed today.
AstraZeneca mulls Astra Tech spin-out
AstraZeneca plc (NYSE:AZN) is shopping around its Astra Tech business.
The pharmaceutical giant said it’s begun a review of "strategic options" for its Swedish dental and medical device unit and hired JP Morgan Chase to help with the review.
Various news outlets reported that AstraZeneca is looking for about $2 billion for the business, which develops and markets dental implants and urological and surgical medical devices, according to the company.